Michael J. Tomsicek

2021 - CRISPR Therapeutics AG

In 2021, Michael J. Tomsicek earned a total compensation of $3.8M as Former Chief Financial Officer at CRISPR Therapeutics AG, a 43% increase compared to previous year.

Compensation breakdown

Option Awards$2,108,763
Salary$435,483
Stock Awards$1,204,920
Other$11,600
Total$3,760,766

Tomsicek received $2.1M in option awards, accounting for 56% of the total pay in 2021.

Tomsicek also received $435.5K in salary, $1.2M in stock awards and $11.6K in other compensation.

Rankings

In 2021, Michael J. Tomsicek's compensation ranked 3,549th out of 12,415 executives tracked by ExecPay. In other words, Tomsicek earned more than 71.4% of executives.

ClassificationRankingPercentile
All
3,549
out of 12,415
71st
Division
Manufacturing
1,456
out of 5,505
74th
Major group
Chemicals And Allied Products
590
out of 2,375
75th
Industry group
Drugs
527
out of 2,096
75th
Industry
Biological Products, Except Diagnostic Substances
138
out of 449
69th
Source: SEC filing on April 25, 2022.

Tomsicek's colleagues

We found five more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2021.

2021

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2021

Brendan Smith

CRISPR Therapeutics AG

Chief Financial Officer

2021

Tony Ho

CRISPR Therapeutics AG

Former EVP, Research and Development

2021

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2021

James Kasinger

CRISPR Therapeutics AG

General Counsel

News

In-depth

You may also like